Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

NCT06300528 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Pemigatinib

Sponsor

University of Utah

Collaborators

[object Object]